Eli Lilly and Co. plans to invest over $1 billion to create a new manufacturing site, along with nearly 600 new jobs in Concord, NC. The new facility will use the latest technology to manufacture parenteral (injectable) products and devices and increase the company’s manufacturing capacity.
 
Lilly selected Concord because of the manufacturing technology experience of the local labor force; its proximity to universities, technology, engineering and math programs; and its access to major transportation infrastructure. In 2020, Lilly announced a $470 million investment in NC’s Research Triangle Park. 
 
Lilly plans to create nearly 600 new jobs for highly skilled workers such as scientists, engineers and manufacturing personnel, who will use advanced technology to produce treatments and devices for people around the world. In addition, an estimated 500 additional positions will be required while the facility is under construction.
 
Over the last five years, Lilly has invested over $4 billion in global manufacturing, including more than $2 billion in the U.S. The company also announced plans to invest $500 million in a new biopharmaceutical manufacturing facility in Limerick, Ireland. Lilly anticipates additional future investments in manufacturing to address growth expected from potential new medicines to treat diabetes, Alzheimer’s disease, cancer and autoimmune conditions.

“Lilly is entering an exciting period of growth and we are committed to delivering innovative medicines to patients around the world,” said Edgardo Hernandez, senior vice president and president, Lilly Manufacturing Operations. “Expanding our manufacturing footprint in North Carolina enables us to continue to produce today’s medicines while providing additional capacity to manufacture the medicines of tomorrow. We are pleased to again partner with North Carolina to bring jobs to American workers and provide more medicines that patients need to address health challenges.”